<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600193</url>
  </required_header>
  <id_info>
    <org_study_id>IOOAIOP</org_study_id>
    <nct_id>NCT04600193</nct_id>
  </id_info>
  <brief_title>a Randomized Controlled Trial of the Intake of Organic and Inorganic Phosphate in Peritoneal Dialysis Patients</brief_title>
  <acronym>RCTOIP</acronym>
  <official_title>a Randomized Controlled Trial of the Intake of Organic and Inorganic Phosphate in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stine Kristensen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gita Krüger Mørch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rizwan Butt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ditte Hansen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperphosphatemia is a common problem among patientens suffering from chronic kidney disease.&#xD;
      Hyperphosphatemia is associated with increased risk of cardiovascular diseases. One of the&#xD;
      treatments are through the diet, where patients are instructed ind reducing their daily&#xD;
      intake of phosphate. But since phosphate exists in both organic and inorganic forms in the&#xD;
      diet, this leads to several problems. Informations of the bioavability and furthermore the&#xD;
      effect of plasma koncentrations of phosphate are lacking for both forms of phosphate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of phosphate</measure>
    <time_frame>six days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in p-phosphate</measure>
    <time_frame>six days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in p-calcium</measure>
    <time_frame>six days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in p-sodium</measure>
    <time_frame>six days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in p-potassium</measure>
    <time_frame>six days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in p-PTH</measure>
    <time_frame>six days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in p-FGF23</measure>
    <time_frame>six days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in p-magnesium</measure>
    <time_frame>six days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Koncentration of phosphate in peritoneal dialysis fluid</measure>
    <time_frame>six days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Koncentration of phosphate in urine</measure>
    <time_frame>six days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Chronic Kidney Disease Requiring Chronic Dialysis</condition>
  <arm_group>
    <arm_group_label>Phosphate modified diet with organic phosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phosphate modified diet with inorganic phosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet containing organic phosphate</intervention_name>
    <description>The patients will be receiving a 5 days diet containing organic phosphate</description>
    <arm_group_label>Phosphate modified diet with organic phosphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet containing inorganic phosphate</intervention_name>
    <description>The patients will be receiving a 5 days diet containing inorganic phosphate</description>
    <arm_group_label>Phosphate modified diet with inorganic phosphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 18 years&#xD;
&#xD;
          -  Competent&#xD;
&#xD;
          -  The patient should be able to take a sample of p-fluid and urine by himself&#xD;
&#xD;
          -  Chronic peritoneal dialysis&#xD;
&#xD;
          -  Reads and understand danish&#xD;
&#xD;
          -  Has been informed written and oraly about the study and signed informed consent&#xD;
&#xD;
          -  P-phosphate koncentrations 0,7-2,0 .mol/l&#xD;
&#xD;
          -  P - ioniset calcium 1,1-1,4 mmol/l&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Terminal patients&#xD;
&#xD;
          -  If the experience acute infections or other acute situations they will be excluded&#xD;
             from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Rikardt Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Rikardt Andersen, MD</last_name>
    <phone>+4523346652</phone>
    <email>jra@nexs.ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stine Rikardt Kristensen</last_name>
    <phone>+4528967003</phone>
    <email>stinekristensen@live.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Ditte Hansen, MD</last_name>
      <phone>+4538682056</phone>
      <email>ditte.hansen.04@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Jens Rikardt Andersen</investigator_full_name>
    <investigator_title>Associate professor at the university of Copenhagen</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

